Abstract:The identification of mutations that enhance antibody affinity while maintaining high antibody specificity and stability is a time-consuming and laborious process. Here, we report an efficient methodology for systematically and rapidly enhancing the affinity of antibody variable domains while maximizing specificity and stability using novel synthetic antibody libraries. Our approach first uses computational and experimental alanine scanning mutagenesis to identify sites in the complementarity-determining regions (CDRs) that are permissive to mutagenesis while maintaining antigen binding. Next, we mutagenize the most permissive CDR positions using degenerate codons to encode wild-type residues and a small number of the most frequently occurring residues at each CDR position based on natural antibody diversity. This mutagenesis approach results in antibody libraries with variants that have a wide range of numbers of CDR mutations, including antibody domains with single mutations and others with tens of mutations. Finally, we sort the modest size libraries (~10 million variants) displayed on the surface of yeast to identify CDR mutations with the greatest increases in affinity. Importantly, we find that single-domain (VHH) antibodies specific for the α-synuclein protein (whose aggregation is associated with Parkinson’s disease) with the greatest gains in affinity (>5-fold) have several (four to six) CDR mutations. This finding highlights the importance of sampling combinations of CDR mutations during the first step of affinity maturation to maximize the efficiency of the process. Interestingly, we find that some natural diversity mutations simultaneously enhance all three key antibody properties (affinity, specificity, and stability) while other mutations enhance some of these properties (e.g., increased specificity) and display trade-offs in others (e.g., reduced affinity and/or stability). Computational modeling reveals that improvements in affinity are generally not due to direct interactions involving CDR mutations but rather due to indirect effects that enhance existing interactions and/or promote new interactions between the antigen and wild-type CDR residues. We expect that natural diversity mutagenesis will be useful for efficient affinity maturation of a wide range of antibody fragments and full-length antibodies.

A review of in vitro stochastic and non-stochastic affinity maturation strategies for phage display derived monoclonal antibodies

In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties

Affinity maturation of antibody fragments: A review encompassing the development from random approaches to computational rational optimization

Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis

Generating Recombinant Antibodies to Membrane Proteins through Phage Display

Microfluidics, an effective tool for supporting phage display-A review

Evolution of phage display libraries for therapeutic antibody discovery

Developing recombinant antibodies by phage display technology to neutralize viral infectious diseases

Simultaneous Maturation of Single Chain Antibody Stability and Affinity by CHO Cell Display

The role of phage display in therapeutic antibody discovery

Advancement in the development of single chain antibodies using phage display technology

Improving Antibody Affinity Through in Vitro Mutagenesis in Complementarity Determining Regions

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

Advancements in mammalian display technology for therapeutic antibody development and beyond: current landscape, challenges, and future prospects

Mammalian cell display for the discovery and optimization of antibody therapeutics

Advances in Studies on Phage Display Systems

Modification of phage display technique for improved screening of high-affinity binding peptides

Phage Display Technology as a Powerful Platform for Antibody Drug Discovery

Mammalian Cell Display Technology Coupling with AID Induced SHM in Vitro: an Ideal Approach to the Production of Therapeutic Antibodies.

In vitro evolution of diagnostic antibodies targeting native antigens in plasma by sandwich flow cytometry

Affinity Maturation of an TpoR Targeting Antibody in Full-Length IgG Form for Enhanced Agonist Activity